Abstract 167P
Background
Immune Checkpoint Inhibitors (ICIs) are pivotal in the treatment of late stage NSCLC. Currently, PDL1-high (TPS>=50%) patients generally receive ICI alone, while PDL1 low and negative patients typically receive chemoimmunotherapy (chemo-ICI). However, many patients in both groups fail to respond, suggesting opportunities for more effective intervention - particularly PDL1 high patients who may benefit from escalation to chemo-ICI. We developed an AI-based digital pathology immunotherapy response (PIRe) score based upon tumor infiltrating lymphocyte density (denTIL) and their spatial interactions with tumor cells (spaTIL).
Methods
Pre-treatment hematoxylin and eosin (H&E) stained whole slide images (WSIs) of patients with mostly late stage NSCLC (94.3% stage III/IV, 5.7% stage I/II) treated with ICI were collected from 3 institutions (D1-D3). Nuclei of tumor cells and TIL were segmented and classified automatically via the Picture Health Px platform for spaTIL and denTIL feature calculation. A neural network classifier was trained with these features on a training set (D1 + D2, N = 77) for primary adenocarcinoma and squamous cell carcinoma to predict objective response (OR). PIRe, PDL1 TPS, and a combined PIRe+PDL1 model were then tested on an external test set (D3, N=29) of ICI and chemo-ICI recipients.
Results
PIRe included 5 features, such as morphology of TIL clusters and abundance of TILs surrounding tumor cells. Overall test AUC was 0.71 with 0.82 for ICI and 0.66 for chemo-ICI. PIRe was significantly elevated among responders to ICI (p=0.04, n=11), but not to chemo-ICI (p=0.14, n=16), as assessed by one-sided Wilcoxon rank-sum test. When combined, PDL1 and PIRe consistently outperformed PDL1 TPS alone (Table). Table: 167P
AUC for ICI response prediction with different models for different treatment subgroups
AUC | All treatments (n=29) | ICI only (n=11) | chemo-ICI only (n=18) |
PIRe | 0.71 | 0.82 | 0.60 |
PDL1 (TPS) IHC | 0.76 | 0.75 | 0.81 |
PDL1 IHC + PIRe | 0.82 | 0.96 | 0.85 |
Conclusions
PIRe predicted ICI response in NSCLC patients, showing added value to PDL1. Further validation in larger cohorts to confirm these promising early findings is essential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Picture Health.
Disclosure
A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult.: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. N. Braman: Financial Interests, Personal, Stocks/Shares: Picture Health, Tempus Labs. All other authors have declared no conflicts of interest.
Resources from the same session
162P - Exploiting gp100-specific antibodies isolated from immune checkpoint inhibitor-responsive melanoma patients to target tumor cells
Presenter: Lukas Flatz
Session: Poster session 08
163P - Tumorspheres cultured from circulating cancer stem cells overexpress the innate checkpoint CD47 in breast cancer patients
Presenter: Monika Pizon
Session: Poster session 08
Resources:
Abstract
164P - A spatially informed transcriptomic model to forecast early resistance to front-line osimertinib in advanced EGFR-mutant NSCLC
Presenter: Jon Zugazagoitia
Session: Poster session 08
165P - Consistency analysis of c-Met protein expression over time in patients with non-squamous non-small cell lung cancer
Presenter: Alexis Cortot
Session: Poster session 08
166P - Integrative multi-omics refine molecular diagnostics in non-small cell lung cancer
Presenter: Li Ren Kong
Session: Poster session 08
168P - Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients
Presenter: Himanshu Grover
Session: Poster session 08
169P - Analysis of tumor immune microenvironment with mIHC in Chinese non-small cell lung cancer
Presenter: Hao Wu
Session: Poster session 08
170P - Clinical presentations and prognosis of HER2-low breast cancer in Taiwan
Presenter: Grace Chen
Session: Poster session 08
171P - A computational pathology collagen signature predictive of tamoxifen benefit in ductal carcinoma in situ: Results from a cohort within the UK/ANZ DCIS randomized trial
Presenter: Arpit Aggarwal
Session: Poster session 08
172P - HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd)
Presenter: Ahmed Ismail
Session: Poster session 08